allogeneic TSCM-rich dual CAR-T therapy / Roche - LARVOL DELTA

Poseida Therapeutics Announces Nomination of New CAR-T Development Candidate Under Collaboration with Roche (PRNewswire) - "Poseida Therapeutics, Inc....today announced the nomination of a new development candidate under its collaboration with Roche. The nomination triggered a $15 million milestone payment from Roche to Poseida...The new candidate is an allogeneic, dual CAR-T therapy targeting known antigens expressed in hematologic malignancies, including multiple myeloma. The large capacity of Poseida's non-viral transposon-based DNA delivery system enables the insertion of genes for two full length chimeric antigen receptors (CARs) into T stem cell memory cells (TSCM)."

New molecule • Hematological Malignancies • Multiple Myeloma • Oncology